Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 14,556 | 9,499 | 8,945 | 14,703 | 4,341 |
| Cost of Goods | 146 | 334 | 671 | 728 | 1,426 |
| Gross Profit | 14,410 | 9,165 | 8,274 | 13,975 | 2,915 |
| Operating Expenses | 51,175 | 30,977 | 33,678 | 37,223 | 52,552 |
| Operating Income | -36,619 | -21,478 | -24,733 | -22,520 | -49,211 |
| Interest Expense | -1,691 | -1,715 | -1,629 | -829 | 0 |
| Other Income | -33,719 | 1,181 | -178 | -4,121 | 5,941 |
| Pre-tax Income | -68,647 | -18,582 | -23,282 | -25,812 | -43,270 |
| Income Tax | -5,280 | N/A | -1,803 | 541 | N/A |
| Net Income Continuous | -63,367 | -18,582 | -21,479 | -26,353 | -43,270 |
| Minority Interests | 166 | 27 | 7 | -80 | -251 |
| Net Income | $-63,533 | $-18,609 | $-21,486 | $-26,273 | $-43,019 |
| EPS Basic Total Ops | -0.28 | -0.09 | -0.12 | -0.15 | -0.26 |
| EPS Basic Continuous Ops | -0.28 | -0.09 | -0.12 | -0.16 | -0.26 |
| EPS Diluted Total Ops | -0.28 | -0.09 | -0.12 | -0.15 | -0.26 |
| EPS Diluted Continuous Ops | -0.28 | -0.09 | -0.12 | -0.16 | -0.26 |
| EPS Diluted Before Non-Recurring Items | -0.16 | -0.09 | -0.12 | -0.15 | -0.19 |
| EBITDA(a) | $-21,138 | $-20,911 | $-23,950 | $-21,828 | $-48,324 |